“We may be tempted to conclude a causal relationship based on the results of this analysis; however, we should avoid making statements implying a causal relationship,” says Jaleh Fallah, MD.
In this video, Jaleh Fallah, MD, discusses findings from the Journal of the National Cancer Institute paper, “Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a U.S. FDA pooled analysis.” Fallah is a medical oncologist with the FDA.
As I mentioned earlier, we did not include the trial of ipilimumab and nivolumab in this analysis, and the combination of atezolizumab and bevacizumab that we included in the pool has not been approved for treatment of RCC. However, the other 4 trials that were included in this pooled analysis led to FDA approval of the investigative combinations of immune checkpoint inhibitor and VEGF TKI.
We may be tempted to conclude a causal relationship based on the results of this analysis; however, we should avoid making statements implying a causal relationship. For example, we cannot say that cytoreductive nephrectomy improves patient outcomes, and we cannot conclude it provides any benefit in this setting. Our analysis only demonstrated an association, which may be due to the effects of nephrectomy or confounding factors associated with patient selection for nephrectomy, or both. And to answer this question, we need a randomized trial.
This transcription was edited for clarity.
Mitochondrial metabolism may promote kidney cancer metastasis, new data show
August 14th 2024“The challenge now is to understand how these key aspects of mitochondrial metabolism become activated, why they stimulate metastasis, and whether we can safely block them,” says Ralph J. DeBerardinis, MD, PhD.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.